[HTML][HTML] Effectiveness and safety of non-vitamin K antagonist oral anticoagulant in the treatment of patients with morbid obesity or high body weight with venous …
H Zhang, H Xie, X Wang, Z Zhu, F Duan - Medicine, 2023 - journals.lww.com
Background: Venous thromboembolism (VTE) poses a significant health risk to patients with
morbid obesity or high body weight. Non-vitamin K antagonist oral anticoagulants (NOACs) …
morbid obesity or high body weight. Non-vitamin K antagonist oral anticoagulants (NOACs) …
Effectiveness and safety of non-vitamin K antagonist oral anticoagulant in the treatment of patients with morbid obesity or high body weight with venous …
H Zhang, H Xie, X Wang, Z Zhu, F Duan - Medicine, 2023 - europepmc.org
Background Venous thromboembolism (VTE) poses a significant health risk to patients with
morbid obesity or high body weight. Non-vitamin K antagonist oral anticoagulants (NOACs) …
morbid obesity or high body weight. Non-vitamin K antagonist oral anticoagulants (NOACs) …
[HTML][HTML] Effectiveness and safety of non-vitamin K antagonist oral anticoagulant in the treatment of patients with morbid obesity or high body weight with venous …
H Zhang, H Xie, X Wang, Z Zhu, F Duan - Medicine, 2023 - ncbi.nlm.nih.gov
Background: Venous thromboembolism (VTE) poses a significant health risk to patients with
morbid obesity or high body weight. Non-vitamin K antagonist oral anticoagulants (NOACs) …
morbid obesity or high body weight. Non-vitamin K antagonist oral anticoagulants (NOACs) …
Effectiveness and safety of non-vitamin K antagonist oral anticoagulant in the treatment of patients with morbid obesity or high body weight with venous …
H Zhang, H Xie, X Wang, Z Zhu, F Duan - Medicine, 2023 - ingentaconnect.com
Background: Venous thromboembolism (VTE) poses a significant health risk to patients with
morbid obesity or high body weight. Non-vitamin K antagonist oral anticoagulants (NOACs) …
morbid obesity or high body weight. Non-vitamin K antagonist oral anticoagulants (NOACs) …
Effectiveness and safety of non-vitamin K antagonist oral anticoagulant in the treatment of patients with morbid obesity or high body weight with venous …
H Zhang, H Xie, X Wang, Z Zhu, F Duan - Medicine, 2023 - pubmed.ncbi.nlm.nih.gov
Background Venous thromboembolism (VTE) poses a significant health risk to patients with
morbid obesity or high body weight. Non-vitamin K antagonist oral anticoagulants (NOACs) …
morbid obesity or high body weight. Non-vitamin K antagonist oral anticoagulants (NOACs) …
Effectiveness and safety of non-vitamin K antagonist oral anticoagulant in the treatment of patients with morbid obesity or high body weight with venous …
H Zhang, H Xie, X Wang, Z Zhu, F Duan - Medicine, 2023 - europepmc.org
Background Venous thromboembolism (VTE) poses a significant health risk to patients with
morbid obesity or high body weight. Non-vitamin K antagonist oral anticoagulants (NOACs) …
morbid obesity or high body weight. Non-vitamin K antagonist oral anticoagulants (NOACs) …